Cargando…
The neuropsychiatric complications of stimulant abuse /
This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on the neuropsychiatric complications of stimulant abuse.<br><br><ul><li>Brings together c...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Waltham, MA :
Academic Press,
2015.
|
| Edición: | First edition. |
| Colección: | International review of neurobiology ;
v. 120. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; The Neuropsychiatric Complications of Stimulant Abuse; Copyright; Contents; Contributors; Chapter One: The Story of ��Speed�� from ��Cloud Nine�� to Brain Gain; References; Chapter Two: Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses; 1. Introduction; 2. Early History of the Amphetamines; 3. Wakefulness, Attention, and Cognitive Performance; 4. Mood Elevation; 5. Appetite Suppression; 6. Military Use: ��Combat Fatigue�� and the Second World War; 7. Nonmedical Use, Abuse, and Dependence; 8. Conclusion; Acknowledgment; References.
- Chapter Three: Miracle or Menace?References; Chapter Four: Psychostimulants: Basic and Clinical Pharmacology; 1. Introduction; 2. Human and Animal Effects of Psychostimulants; 3. Chemistry and Pharmacology of Psychostimulants; 4. Psychostimulant Use Versus Abuse; 4.1. Improved Social Interaction; 4.2. Facilitated Sexual Behavior; 4.3. Improved Cognitive Performance and Counteracting Fatigue; 4.4. Facilitated Recovery and Coping with Psychological Stress; 4.5. Sensory Curiosity-Expanded Perception Horizon and Boredom; 4.6. Euphoria, Hedonia, and High.
- 5. Strategies for the Treatment of Psychostimulant Use Disorder: Clinical and Nonclinical Approaches, Evolving Targets5.1. Pharmacological Strategies; 5.1.1. Dopamine-Based Strategies; 5.1.1.1. l-DOPA; 5.1.1.2. Dexamphetamine; 5.1.1.3. Methylphenidate; 5.1.1.4. Selegiline; 5.1.1.5. Bupropion; 5.1.1.6. Modafinil; 5.1.1.7. Disulfiram; 5.1.1.8. Antipsychotics; 5.1.2. 5-HT-Based Strategies; 5.1.3. GABA-Based Strategies; 5.1.3.1. Gabapentin; 5.1.3.2. Tiagabine; 5.1.3.3. Vigabatrin; 5.1.3.4. Baclofen; 5.1.4. Glutamate-Based Strategies; 5.1.4.1. Ketamine; 5.1.4.2. Memantine.
- 5.1.4.3. N-Acetylcysteine5.1.5. ��Other�� Target-Based Strategies; 5.1.5.1. Acamprosate; 5.1.5.2. Galantamine; 5.1.5.3. Naltrexone; 5.1.5.4. Varenicline; 5.2. Pharmacokinetic/Immuno Strategies; 6. Concluding Remarks; References; Chapter Five: Epigenetic Mechanisms of Psychostimulant-Induced Addiction; 1. Introduction; 2. Epigenetic Processes; 3. Chromatin Structure; 4. Histone Modifications; 4.1. Histone Code; 5. DNA Methylation and Demethylation; 6. Noncoding RNA; 7. Epigenetic Mechanisms in Psychostimulant-Induced Addiction.
- 7.1. Role of Histone Modifications in Psychostimulant-Induced Addiction7.1.1. Histone Acetylation; 7.1.2. Histone Methylation; 7.1.3. Histone Phosphorylation; 7.2. Role of DNA Methylation in Psychostimulant-Induced Addiction; 7.3. Role of Noncoding RNAs in Addiction; 8. Conclusions; References; Chapter Six: Experimental Models on Effects of Psychostimulants; 1. Introduction; 2. Changes in the Brain in Response to Psychostimulants; 3. Animal Models; 4. Psychostimulant Animal Models; 5. Animal Models to Analyze Reinforcing Properties; 5.1. Intravenous Drug Self-Administration.